OncoMatch/Clinical Trials/NCT06722183
Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities
Is NCT06722183 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Futibatinib orally administered and Tislelizumab (i.v. 200mg) for colorectal cancer.
Treatment: Futibatinib orally administered · Tislelizumab (i.v. 200mg) — The FUTURE trial is a prospective, multicentre, exploratory, open-label phase II platform trial. Its goal is to evaluate the efficacy, feasibility and safety of futibatinib combined with immunotherapeutic, targeted or chemotherapeutic agents in colorectal and other solid tumors and to additionally identify biomarkers that correlate with clinical outcome.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: KRAS status known
with known RAS-, BRAF and MSI- status
Required: NRAS status known
with known RAS-, BRAF and MSI- status
Required: BRAF status known
with known RAS-, BRAF and MSI- status
Required: MSH2 status known
with known RAS-, BRAF and MSI- status
Required: MSH6 status known
with known RAS-, BRAF and MSI- status
Required: MLH1 status known
with known RAS-, BRAF and MSI- status
Required: PMS2 status known
with known RAS-, BRAF and MSI- status
Disease stage
Excluded: Stage CURATIVE
Metastatic disease required
unresectable and/or metastatic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: FGFR inhibitor
Patient received previous FGFR-addressed therapy with an FGFR inhibitor.
Cannot have received: PD-(L)1 or CTLA-4 targeted treatment
Patient received prior treatment with PD-(L)1 or CTLA-4 targeted treatment
Lab requirements
Blood counts
ANC > 1,500 cells/μL without the use of hematopoietic growth factors; Platelet count ≥ 100 x 10^9/L (>100,000 per mm3); Hemoglobin ≥ 9 g/dL, transfusion allowed
Kidney function
Serum Creatinine ≤ 1.5 x ULN and a calculated creatinine clearance rate ≥ 50 mL /min
Liver function
Serum total bilirubin ≤ 1.5x institutional ULN (or < 2 x ULN in case of liver involvement or Gilbert's disease); AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional ULN without existing liver metastases, or ≤ 5 x UNL in the presence of liver metastases; AP ≤ 5 x ULN
Patient has adequate blood count, liver-enzymes, and renal function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify